Evidence map›Paper›PMID 28490569›Full record

ArticleBlood2017

Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma.

Pier Luigi Zinzani, Vincent Ribrag, Craig H Moskowitz, Jean-Marie Michot, John Kuruvilla, Arun Balakumaran, Yayan Zhang, Sabine Chlosta, Margaret A Shipp, Philippe Armand

Registry-linked trialOpen access · bronzeAbstract readClinical Trial, Phase IMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01953692 (A Phase Ib Multi-Cohort Trial of MK-3475), which is not on this map. Cited by 154 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
154citing papers in PubMed, 5 pooled it
34.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01953692 phase1completednot on this map

A Phase Ib Multi-Cohort Trial of MK-3475 (Pembrolizumab) in Subjects With Hematologic Malignancies

TypeinterventionalSponsorMerck Sharp & Dohme LLCRan2013 to 2020Enrolled197ConditionsMyelodysplastic Syndrome, Multiple Myeloma, Hodgkin Lymphoma, Non-Hodgkin LymphomaArmsPembrolizumab, Lenalidomide 20 mg, Lenalidomide 25 mg
3 · Its place in the literature

Who cites it

154 citing papers in PubMed, 5 syntheses or guidelines pooled it, 295 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B Cell Lymphoma.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2019
    Trial
  16. Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019
    Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

94 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 4 countries.

Pier Luigi ZinzaniInstitute of Hematology "L. e A. Seràgnoli," University of Bologna, Bologna, Italy.
Vincent RibragGustave Roussy, Université Paris-Saclay, Département d'hématologie, INSERM U1170, Villejuif, France.
Craig H MoskowitzMemorial Sloan Kettering Cancer Center, New York, NY.
Jean-Marie MichotGustave Roussy, Université Paris-Saclay, Département d'hématologie, INSERM U1170, Villejuif, France.
John KuruvillaPrincess Margaret Cancer Centre and University of Toronto, Toronto, ON, Canada.
Arun BalakumaranMerck & Co., Inc., Kenilworth, NJ; and.
Yayan ZhangMerck & Co., Inc., Kenilworth, NJ; and.
Sabine ChlostaMerck & Co., Inc., Kenilworth, NJ; and.
Margaret A ShippDana-Farber Cancer Institute, Boston, MA.
Philippe ArmandDana-Farber Cancer Institute, Boston, MA.
Merck & Co., Inc., Rahway, NJ, USA (United States) · USDana-Farber Cancer Institute · USInserm · FRMemorial Sloan Kettering Cancer Center · USUniversité Paris-Saclay · FRUniversity of Bologna · ITUniversity of Toronto · CA

Funding

Targetable Immune Evasion Pathways in Hodgkin LymphomaR01CA161026 · NCI · DANA-FARBER CANCER INST · PI SHIPP, MARGARET A · 2011 to 2020
$4.0M
NCI NIH HHS R01 CA161026
6 · The paper itself

Abstract

Treatment options for relapsed/refractory primary mediastinal large B-cell lymphoma (rrPMBCL) are limited, and prognosis is generally poor (overall response rate [ORR] 0% to 25%; 2-year overall survival 15%). PMBCL frequently involves PD-1 ligand overexpression, potentially making PMBCL particularly susceptible to PD-1 blockade. We evaluated safety and antitumor activity of pembrolizumab, an anti-PD-1 antibody, in rrPMBCL as part of the KEYNOTE-013 multicohort phase 1b trial. At time of data cutoff, 18 patients (median age 30 years; median 3 prior lines of therapy) had been enrolled and treated, of whom 17 were included in the efficacy analyses. Eleven patients (61%) experienced drug-related adverse events (mostly grade 1-2); none discontinued treatment due to adverse events. ORR was 41% (7/17); 6 additional patients (35%) had stable disease. Of patients evaluable by imaging, 13 out of 16 (81%) had decreases in target lesions. With a median follow-up of 11.3 months, median duration of response was not reached. Two patients reached the maximum 2-year treatment duration and remain in remission. Median overall survival was not reached for treated patients overall; all responders were still alive at data cutoff. These results in heavily pretreated rrPMBCL patients demonstrate that PD-1 blockade with pembrolizumab has a manageable safety profile and promising antitumor activity. This trial was registered at www.clinicaltrials.gov as #NCT01953692.

Indexed as

AdultAntibodies, Monoclonal, HumanizedAntineoplastic AgentsDrug Administration ScheduleFemaleGene ExpressionHumansLymphoma, Large B-Cell, DiffuseMaleMediastinal NeoplasmsNeoplasm Recurrence, LocalPatient SafetyPrognosisProgrammed Cell Death 1 ReceptorSurvival AnalysisTreatment OutcomeAntibodies, Monoclonal, HumanizedAntineoplastic AgentsPDCD1 protein, humanpembrolizumabProgrammed Cell Death 1 Receptor

Identifiers

PMID28490569
PMCPMC5766837
OpenAlexW2612422239

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.